toll-like receptor 3 signal in dendritic cells benefits cancer immunotherapy

Tiklamalar: 320
ID: 181800
2017
Ucretsiz PDF
Makale Kalitesi ve Performans Metrikleri
Genel Kalite
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
Yapay Zeka Kalite Degerlendirmesi
Analiz edilmedi
Readership in this journal
Steady

Ranked #209 of 644 articles by views in sudebno-meditsinskaia ekspertiza

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 644 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Ozet
Pattern recognition receptors (PRRs) play a crucial role in the innate immune system and contribute to host defense against microbial infection. PRR-mediated antimicrobial signals provide robust type-I IFN/cytokine production and trigger inflammation, thereby affecting tumor progression and autoimmune diseases. Accumulating evidence demonstrates that among the PRRs, only the signaling pathway of endosomal toll-like receptor 3 (TLR3) induces no systemic inflammation and mediates cross-priming of antigen-specific CD8+ T cells by dendritic cells. Treatment with a newly developed TLR3-specific ligand, ARNAX, along with tumor-associated antigens (TAAs), induces tumor-specific cytotoxic T lymphocytes, modulates the tumor microenvironment to establish Th1-type antitumor immunity, and leads to tumor regression without inflammation in mouse tumor models. Combination therapy using ARNAX/TAA and PD-1/PD-L1 blockade potently enhances antitumor response and overcomes anti-PD-1/PD-L1 resistance. In this review, we will discuss the TLR3-mediated signaling in antitumor immunity and its application to cancer immunotherapy.
Referans Anahtari
matsumoto2017frontierstoll-like Kullanarak makale yazarken otomatik alinti icin bu anahtari kullanin SciMatic Makale Yoneticisi veya Tez Yoneticisi
Yazarlar ;Misako Matsumoto;Yohei Takeda;Megumi Tatematsu;Tsukasa Seya
Dergi sudebno-meditsinskaia ekspertiza
Yil 2017
DOI
10.3389/fimmu.2017.01897
URL
http://journal.frontiersin.org/article/10.3389/fimmu.2017.01897/full
Anahtar Kelimeler
adjuvant cancer immunotherapy checkpoint inhibitors dendritic cells allergy

Atiflar

Atif bulunamadi. Atif eklemek icin yoneticiyle iletisime gecin: info@scimatic.org

Yorumlar

Henuz yorum yok. Bu makaleye ilk yorumu siz yapin.